Related by context. All words. (Click for frequent words.) 74 acute myelogenous leukemia AML 72 acute myeloid leukemia 72 chronic lymphocytic leukemia CLL 69 leukemia AML 68 chronic myelogenous leukemia CML 68 Acute Myeloid Leukemia AML 68 myelodysplastic syndrome MDS 68 chronic myeloid leukemia CML 65 glioblastoma multiforme GBM 64 Acute Myeloid Leukemia 64 DLBCL 64 leukemia ALL 64 lupus nephritis 64 myelodysplastic syndromes MDS 63 metastatic colorectal cancer 63 NSCLC 63 myelodysplastic syndromes 63 follicular lymphoma 63 systemic lupus erythematosus 63 glioblastoma 63 acute myelogenous leukemia 63 systemic lupus erythematosus SLE 63 leukemias 62 multiple myeloma 62 leukemia CLL 62 metastatic renal cell carcinoma 61 CLL 61 hormone refractory prostate cancer 61 advanced NSCLC 61 indolent NHL 61 HER2 positive metastatic breast 61 refractory acute myeloid 61 relapsing remitting multiple sclerosis 61 untreated de novo 61 Hodgkin lymphoma NHL 61 juvenile idiopathic arthritis JIA 61 atypical hemolytic uremic syndrome 61 lymphoma CTCL 61 acute lymphoblastic leukemia 61 aHUS 61 Cloretazine 60 cutaneous T cell 60 medulloblastoma 60 lymphomas 60 rheumatoid arthritis RA 60 leukaemias 60 Ph + ALL 60 gastrointestinal stromal tumors 60 dasatinib 60 metastatic melanoma 60 acute leukemia 60 ependymoma 60 imatinib resistant 60 B CLL 60 non metastatic osteosarcoma 60 leukemia CML 59 remission induction 59 Gleevec resistant 59 HER2 positive breast cancer 59 heavily pretreated 59 cell lymphoma CTCL 59 T#I mutation 59 Acute myeloid leukemia AML 59 myelodysplastic syndrome 59 refractory chronic lymphocytic 59 Acute lymphoblastic leukemia 59 Acute Myelogenous Leukemia AML 59 multiple myeloma MM 59 homozygous familial hypercholesterolemia 59 Myelodysplastic syndromes 59 mRCC 59 hypophosphatasia 59 hematologic malignancies 59 follicular lymphoma FL 59 nilotinib 59 adverse cytogenetics 59 relapsing remitting 59 renal cell carcinoma 59 pancreatic adenocarcinoma 59 recurrent glioblastoma 59 Ph + CML 59 lymphocytic leukemia 59 myeloid 59 relapsed refractory AML 59 acute leukemias 59 Amrubicin 58 mCRC 58 familial hypercholesterolemia 58 medullary thyroid cancer 58 Chronic lymphocytic leukemia 58 myelofibrosis 58 Non Hodgkin lymphoma 58 Myelofibrosis 58 follicular NHL 58 hepatocellular cancer 58 hypereosinophilic syndrome 58 Glioblastoma 58 squamous cell carcinoma SCC 58 idiopathic pulmonary fibrosis IPF 58 relapsing remitting MS 58 neuroblastoma 58 geographic atrophy 58 hematological malignancy 58 mCRC patients 58 phase IIb clinical 58 relapsed refractory 58 acute myeloid 57 diabetic nephropathy 57 HRPC 57 solid tumors 57 SJIA 57 de novo AML 57 imatinib Gleevec 57 chronic granulomatous disease 57 leukemic 57 recurrent ovarian cancer 57 relapsed refractory multiple myeloma 57 chronic lymphocytic leukemia 57 recurrent glioblastoma multiforme 57 colorectal cancer CRC 57 Alemtuzumab 57 cystic fibrosis CF 57 acute promyelocytic leukemia APL 57 MALT lymphoma 57 castration resistant prostate cancer 57 hematological malignancies 57 castrate resistant prostate cancer 57 Omacetaxine 57 Hodgkin lymphoma HL 57 hematologic disorders 57 diagnosed Ph + 57 pomalidomide 57 malignant pleural mesothelioma 57 refractory chronic myeloid 57 standard chemotherapy regimens 57 Chronic Lymphocytic Leukemia CLL 57 metastatic malignant melanoma 57 Philadelphia Chromosome Positive 57 nonsmall cell lung cancer 57 leukemia APL 57 hematological cancers 57 Chronic lymphocytic leukemia CLL 57 essential thrombocythemia 57 chronic myeloid 57 purpura ITP 57 Leber congenital amaurosis LCA 57 severe sepsis 57 cutaneous T 57 Parkinson disease PD 57 Leber Congenital Amaurosis LCA 57 azacitidine 57 brain metastases 57 secondary hyperparathyroidism 57 KRAS wild 57 Acute Myeloid Leukaemia AML 57 chronic myelogenous leukemia 57 eosinophilic asthma 56 clofarabine 56 bevacizumab Avastin ® 56 prostate cancer CRPC 56 pancreatic NET 56 metastatic colon cancer 56 ara C 56 myeloproliferative diseases 56 AA amyloidosis 56 Rituxan rituximab 56 BCR ABL 56 hepatocellular carcinoma HCC 56 myelofibrosis polycythemia vera 56 soft tissue sarcomas 56 acute promyelocytic leukemia 56 Acute myeloid leukemia 56 TTR amyloidosis 56 chronic myeloid leukemia 56 chronic eosinophilic leukemia 56 sapacitabine 56 metastatic renal cell 56 myeloproliferative neoplasms 56 primary hypercholesterolemia 56 chlorambucil 56 Follicular lymphoma 56 juvenile myelomonocytic leukemia 56 relapsed AML 56 T1DM 56 myeloproliferative disorder 56 Glioblastoma Multiforme 56 Cloretazine R VNP#M 56 hypomethylating agents 56 Hurler syndrome 56 platinum refractory 56 hematologic cancers 56 grade gliomas 56 lymphoblastic leukemia 56 pulmonary arterial hypertension 56 dasatinib Sprycel 56 bendamustine 56 basal cell nevus syndrome 56 autoantibody positive 56 pediatric acute lymphoblastic 56 grade cervical intraepithelial 56 vinorelbine 56 Non Hodgkin Lymphoma 56 gastrointestinal stromal tumor GIST 56 Chronic Myeloid Leukemia 56 familial amyloidotic polyneuropathy FAP 56 PCNSL 55 galiximab 55 MYCN amplification 55 soft tissue sarcoma 55 elevated triglyceride levels 55 Cell Lymphoma 55 Wilms tumor 55 hepatocellular carcinoma 55 Marqibo 55 metastatic cancer 55 operable breast cancer 55 IV metastatic melanoma 55 Follicular Lymphoma 55 T#I [002] 55 AML 55 tyrosine kinase inhibitors 55 non Hodgkin lymphomas 55 resistant ovarian cancer 55 cancers 55 sarcomas 55 Vidaza ® 55 invasive candidiasis 55 metastatic malignant 55 prostate cancer CaP 55 epithelial tumors 55 neuroendocrine tumors 55 refractory AML 55 ADPKD 55 paroxysmal nocturnal hemoglobinuria PNH 55 CHOP chemotherapy 55 Onrigin 55 INCB# [001] 55 chronic immune thrombocytopenic 55 chemotherapy regimens 55 dasatinib Sprycel ® 55 lumiliximab 55 Acute Myelogenous Leukemia 55 CLL SLL 55 Waldenstrom macroglobulinemia 55 metastatic kidney 55 Diffuse Large B 55 brain tumor glioblastoma multiforme 55 phase Ph + 55 voreloxin 55 metastatic castration resistant 55 leukemia 55 malignancies 55 metastatic uveal melanoma 55 follicular non 55 EGFR inhibitors 55 recurrent NSCLC 55 familial ALS 55 rALLy 55 receptor tyrosine kinase inhibitor 55 idiopathic thrombocytopenic purpura ITP 55 refractory CML 55 mycosis fungoides 55 imatinib Gleevec ® 55 cutaneous melanoma 55 atypical Hemolytic Uremic Syndrome 55 obatoclax 55 neuroblastomas 55 Myelodysplastic syndromes MDS 55 systemic juvenile idiopathic 55 Cholangiocarcinoma 55 systemic ALCL 55 chronic plaque psoriasis 55 osteosarcoma 55 sorafenib 55 Alzheimer disease AD 55 lupus 55 related macular degeneration 55 Annamycin 55 EGFR mutations 55 papillary renal cell carcinoma 55 Leber Hereditary Optic Neuropathy 55 azacytidine 55 gefitinib Iressa 55 TREANDA 55 cytogenetic responses 55 acne vulgaris 54 decitabine 54 Nilotinib 54 dirucotide 54 Xanafide 54 relapsed multiple myeloma 54 tumors GIST 54 medulloblastomas 54 Chronic Lymphocytic Leukemia 54 relapsed ALL 54 relapsed ovarian cancer 54 hepatitis C genotype 54 diffuse gastric 54 myeloid leukemia 54 Crohn disease 54 malignant gliomas 54 sarcoma 54 uveitis 54 pemphigus vulgaris 54 Fludarabine 54 Myelodysplastic Syndromes MDS 54 Osteosarcoma 54 Clolar 54 alvespimycin 54 ponatinib 54 ovarian carcinoma 54 metastatic hormone refractory 54 Adjuvant chemotherapy 54 KRAS mutations occur 54 bladder carcinoma 54 carcinoid tumors 54 Burkitt lymphoma 54 hypoparathyroidism 54 Glioblastoma Multiforme GBM 54 refractory gout 54 PTLD 54 juvenile idiopathic arthritis 54 Duchenne muscular dystrophy DMD 54 hemolytic anemia 54 diagnosed multiple myeloma 54 non Hodgkin lymphoma 54 common hematologic malignancy 54 Chronic myeloid leukemia 54 hepatitis C HCV 54 unstable angina UA 54 HGS ETR1 54 temsirolimus 54 Acute Lymphoblastic Leukemia 54 pan HDAC inhibitor 54 HSCT 54 Wet AMD 54 recurrent glioblastoma multiforme GBM 54 refractory CTCL 54 breast carcinomas 54 ON #.Na 54 haematologic malignancies 54 enzastaurin 54 non hodgkin lymphoma 54 gastrointestinal stromal tumor 54 acute ischemic stroke 54 erlotinib Tarceva ® 54 sorafenib Nexavar ® 54 rheumatoid arthritis 54 T#I mutant 54 Ph + acute lymphoblastic 54 Dasatinib 54 cell lymphomas 54 metastatic prostate cancer 54 neovascular 54 Haptoglobin 54 astrocytoma 54 serous ovarian cancer 54 hematologic 54 primary generalized tonic 54 chronic HCV infection 54 idiopathic pulmonary fibrosis 54 homozygous FH 54 imatinib 54 refractory indolent non 54 myeloma 54 PAOD 54 Evoltra TM 54 relapsed MM 54 acute coronary syndromes ACS 54 gastrointestinal stromal tumors GIST 54 ATTR PN 54 candidemia 54 HNSCC 54 HuLuc# 54 Velcade bortezomib 54 Hepatocellular Carcinoma HCC 54 neuroendocrine cancers 54 KRAS mutant 54 Campath alemtuzumab 54 grade glioma 54 pheochromocytoma 54 Myelodysplastic Syndrome MDS 54 cisplatin chemotherapy 54 IV NSCLC 54 elacytarabine 54 nonalcoholic steatohepatitis NASH 53 relapsed GBM 53 Cutaneous T 53 Ceflatonin 53 seminoma 53 refractory cutaneous T 53 Glioblastomas 53 anti leukemic 53 HCV infection 53 refractory multiple myeloma 53 eculizumab 53 JMML 53 refractory metastatic colorectal cancer 53 acute lymphocytic leukemia 53 inherited neurodegenerative disorder 53 LymphoStat B belimumab 53 kidney urologic 53 Gleevec imatinib 53 Fludara 53 Primary IGFD 53 hepatic encephalopathy HE 53 proliferative diabetic retinopathy 53 Leukemias 53 cell malignancies 53 Torisel 53 multiple sclerosis MS 53 hepatorenal syndrome 53 myeloid metaplasia 53 bone metastases 53 vandetanib 53 diffuse intrinsic pontine glioma 53 tuberous sclerosis complex 53 complement inhibitor eculizumab 53 IV melanoma 53 cytopenias 53 bortezomib 53 lung fibrosis 53 LHON 53 Kit CD# positive 53 tyrosine kinase inhibitors TKIs 53 dyskeratosis congenita 53 pralatrexate 53 progressive PsA 53 Azedra 53 metastatic HRPC 53 relapsed acute lymphoblastic 53 sunitinib 53 Sjögren syndrome 53 cSSSI 53 AP# [003] 53 AEG# 53 Alzheimer Disease AD 53 lymphoma 53 FLT3 53 Atypical Hemolytic Uremic Syndrome 53 axitinib 53 cetuximab Erbitux ® 53 Crohn disease CD 53 onset diabetes mellitus 53 myeloproliferative disorders 53 mixed dyslipidemia 53 oligodendrogliomas 53 Clofarabine 53 acute coronary syndromes 53 synovial sarcoma 53 glufosfamide 53 carcinoma 53 cell acute lymphoblastic 53 MGd 53 systemic anaplastic large 53 progressive neurodegenerative disorder 53 BRAF mutation 53 schizophrenia CIAS 53 malignant lymphomas 53 K ras mutations 53 Chronic myeloid leukemia CML 53 metaglidasen 53 ATTR 53 anemias 53 non alcoholic steatohepatitis 53 cytogenetic response 53 Idiopathic pulmonary fibrosis 53 tyrosine kinase inhibitor TKI 53 cancer mCRC 53 lintuzumab SGN 53 Ilaris 53 ganetespib 53 thalidomide Thalomid 53 deletion 5q 53 tyrosine kinase inhibitor 53 biologic therapy 53 acute GvHD 53 HER2 overexpression 53 Enzastaurin 53 chronic periodontitis 53 Hereditary angioedema HAE 53 diabetic macular edema 53 proteasome inhibitor bortezomib 53 Rheumatoid Arthritis RA 53 histologies 53 heterozygous FH 53 HBeAg negative 53 unfavorable cytogenetics 53 daunorubicin 53 docetaxel chemotherapy 53 dirucotide MBP# 53 Gleevec imatinib mesylate 53 Lung transplantation 53 hepatocellular carcinomas 53 diabetic retinopathy DR 53 temozolomide 53 ulcerative colitis UC 53 1 diabetes T1D 53 chronic ITP 53 untreated AML 53 Etanercept 53 relapsed Acute Myeloid 53 GvHD 53 palifosfamide 53 INCB# [003] 53 investigational therapies 53 chronic hepatitis C. 53 BRAF gene 53 metastatic breast cancer 53 Idiopathic Pulmonary Fibrosis IPF 53 prostate cancer PCa 53 smoldering myeloma 53 myeloproliferative disease 53 Doxil ® 53 Zolinza 53 sporadic ALS 53 macroalbuminuria 53 alveolar rhabdomyosarcoma 53 IMC A# 53 systolic hypertension 53 fungoides 53 histone deacetylase HDAC inhibitor 52 pertuzumab 52 carcinoid 52 haematologic 52 CYT# potent vascular disrupting 52 squamous cell lung cancer 52 T2DM 52 melanoma 52 metastatic RCC 52 Gorlin syndrome 52 Multiple myeloma 52 trans retinoic acid ATRA 52 heterozygous familial hypercholesterolemia 52 Aortic stenosis 52 invasive aspergillosis 52 MELAS 52 IL# PE#QQR 52 Chronic Myelogenous Leukemia 52 relapsing remitting MS RRMS 52 investigational monoclonal antibody 52 Nexavar sorafenib 52 gastric carcinoma 52 diabetes mellitus 52 erythematosus 52 perifosine 52 FOLFIRI 52 BARACLUDE ® 52 REVLIMID 52 differentiated thyroid 52 small lymphocytic lymphoma 52 low dose cytarabine 52 Triapine 52 tofacitinib 52 GISTs 52 ovarian tumors 52 paclitaxel Taxol ® 52 Glioblastoma multiforme GBM 52 Folfox 52 rhabdomyosarcoma 52 colorectal cancer 52 TORISEL 52 acute leukemia AML 52 MDS AML 52 gastric cancers 52 Synovial sarcoma 52 tanespimycin 52 astrocytomas 52 HeFH 52 alkylating agent 52 relapsed leukemia 52 cell lung cancer 52 proliferative retinopathy 52 diagnosed glioblastoma multiforme 52 adecatumumab 52 rituximab 52 arthritis SJIA 52 myeloproliferative 52 PNP inhibitor 52 prostate cancer HRPC 52 renal disease 52 leukemic stem cells 52 lintuzumab 52 follicular lymphomas 52 Testicular cancer 52 cilengitide 52 anticancer therapy 52 Jevtana 52 lymphoproliferative disorder 52 refractory NSCLC 52 Friedreich ataxia 52 NAGS deficiency 52 Cloretazine R 52 hematological diseases 52 disease NAFLD 52 severe malignant osteopetrosis 52 Sudhir Agrawal D.Phil 52 erlotinib Tarceva 52 Acute Lymphocytic Leukemia 52 tocilizumab 52 Myelodysplastic Syndrome 52 refractory Hodgkin lymphoma 52 primary immunodeficiency PI 52 infantile spasms IS 52 Herceptin trastuzumab 52 Revlimid lenalidomide 52 idiopathic thrombocytopenic purpura 52 antibody MAb 52 dysglycemia 52 relapsing multiple sclerosis 52 Lennox Gastaut syndrome 52 Age Related Macular 52 beta thalassemia 52 Evoltra ® 52 TTF Therapy 52 olaparib 52 basal cell carcinoma BCC 52 neovascular AMD 52 gastrointestinal stromal tumors GISTs 52 anti angiogenic therapy 52 refractory anaplastic astrocytoma 52 acute myelogenous 52 neurological manifestations 52 renal cell carcinomas 52 Ozarelix 52 epithelial ovarian cancer 52 Chronic Myeloid Leukemia CML 52 histologic subtype 52 Novartis Gleevec 52 SPRYCEL ® 52 Parkinson Disease PD 52 metastatic lung cancer 52 CMV infection 52 pneumococcal pneumonia 52 neratinib 52 vWD 52 FLT3 mutations 52 Acute myelogenous leukemia 52 cetuximab Erbitux 52 malignant lymphoma 52 Epratuzumab 52 colorectal carcinoma 52 Hodgkin lymphoma 52 anaplastic lymphoma kinase 52 AA Amyloidosis 52 recurrent GBM 52 Hutchinson Gilford Progeria Syndrome 52 subependymal giant cell 52 Tarceva erlotinib 52 demyelinating 52 Voreloxin 52 indolent lymphomas 52 Vorinostat 52 neurodegenerative disorder 52 EGFR expressing mCRC 52 docetaxel Taxotere R 52 glioblastoma multiforme 52 PKC# 52 ELACYT 52 posterior uveitis 52 Amigal 52 JAK inhibitors 52 Brentuximab Vedotin SGN 52 previously untreated follicular 52 YONDELIS 52 latent tuberculosis infection 52 OHR/AVR# 52 choroidal neovascularization 52 malignant ascites 52 myelodysplastic myeloproliferative diseases 52 FTY# 52 stage IIIB IV 52 amnestic mild cognitive impairment 52 mutated KRAS gene 52 pancreatic carcinoma 52 retinal vein occlusion 52 cabazitaxel 52 Cloretazine ® 52 lupus erythematosus 52 paroxysmal nocturnal hemoglobinuria 52 M2 subunit 52 disease modifying antirheumatic 52 malignant melanoma 52 unresectable 52 haematological cancers 52 anterior uveitis 52 free survival PFS 52 lymphoid malignancies 52 pleural mesothelioma 52 forodesine 52 non Hodgkin Lymphoma 52 Targretin 52 lysosomal storage disease 52 diabetic kidney 52 chemotherapeutic agent 52 cisplatin resistant 52 biliary tract cancer 52 BRAF inhibitor 52 immunodeficiencies 52 monotherapy 52 non squamous NSCLC 52 assessing T DM1 52 Prodarsan ® 52 hyperoxaluria 52 Idiopathic Pulmonary Fibrosis 52 decompensated liver disease 52 DIPG 52 prostate pancreatic 52 nucleoside analogues 52 figitumumab 52 GBM tumors 52 cytotoxic chemotherapy 52 prostate cancer mCRPC 52 receptor inhibitor 52 Alzheimers disease 52 dacetuzumab 52 chemotherapy induced neutropenia 52 hematological 52 luteinizing hormone releasing 52 acute lymphoid leukemia 51 interferon therapy 51 systemic fungal infections 51 acute lymphoblastic 51 Duchenne Muscular Dystrophy DMD 51 Phase #/#a trial 51 grade cervical dysplasia 51 nucleoside 51 Stargardt Disease 51 transthyretin amyloidosis 51 Aplidin 51 mTOR inhibitor 51 alemtuzumab 51 Tasigna nilotinib 51 LUX Lung 51 malignant pancreatic 51 infusional 5-FU/LV 51 gemcitabine Gemzar 51 proteasome inhibitor 51 AVONEX ® 51 non squamous 51 relapsed acute myelogenous 51 Chronic Myelogenous Leukemia CML 51 Rituximab 51 wet macular degeneration 51 hematopoietic cancers 51 MPS IVA 51 TNF antagonist 51 gastric cancer 51 EGFR mutation 51 hereditary angioedema HAE 51 Troxatyl 51 Carcinoid tumors 51 pegylated liposomal doxorubicin 51 vemurafenib 51 RCW Breast Cancer 51 LQTS 51 Vandetanib 51 haematological malignancies 51 targeted radiotherapeutics 51 lung adenocarcinoma 51 neoplasia 51 rALLy clinical trial 51 alpha folate receptor 51 lomitapide 51 NOMID 51 imatinib mesylate 51 Severe Primary IGFD 51 metastatic colorectal carcinoma 51 breast carcinoma 51 thrombocytopenic patients 51 Glioblastoma multiforme 51 autoimmune hemolytic anemia 51 WT1 51 Diabetic Macular Edema 51 rNAPc2 51 paraganglioma 51 Neovascular AMD 51 erlotinib 51 HER2 positive cancers 51 Bortezomib 51 severely active polyarticular 51 HGS ETR2 51 Fabry Disease 51 inoperable pancreatic cancer 51 TTR gene 51 Stomach cancer 51 SCCHN 51 metastatic pancreatic cancer 51 IMA# 51 esophageal candidiasis 51 elotuzumab 51 carcinoid cancer 51 histologically confirmed 51 Multiple sclerosis 51 anticancer compound 51 atherothrombotic events 51 amrubicin 51 Medulloblastoma 51 medically inoperable 51 squalamine 51 Relapsing remitting MS 51 Dacogen injection 51 choroidal vasculopathy 51 Neovascular Age Related Macular 51 osteosarcomas 51 smoldering multiple myeloma 51 virus HCV infection 51 neurogenic orthostatic hypotension 51 metastatic colorectal 51 bone metastasis 51 romiplostim 51 cetuximab Erbitux R 51 radiation sensitizer 51 Fludara ® 51 FSGS 51 MGUS 51 Zarnestra 51 hypercholesterolemia 51 pancreatic neuroendocrine tumors 51 complete cytogenetic response 51 CMV disease 51 KRAS mutations 51 BRIM3 51 Chronic Myeloid Leukaemia 51 blinatumomab 51 RNAi therapeutic targeting 51 symptomatic BPH 51 metastatic GIST 51 canakinumab 51 refractory acute promyelocytic 51 seliciclib 51 alkylating agents 51 RRMS 51 systemic scleroderma 51 congenital hemophilia 51 AMN# [001] 51 pulmonary arterial hypertension PAH 51 thrombocytopenic 51 serologically active systemic lupus 51 HER2 + 51 VEGF Trap 51 lymphoma subtypes 51 NF1 51 MYDICAR ® 51 TACI Ig 51 chronic GVHD 51 severe psoriasis 51 CCyR 51 allogeneic bone marrow 51 DMARD 51 allergic asthma 51 hematopoietic malignancies 51 aflibercept VEGF Trap 51 prostate adenocarcinoma 51 Alocrest 51 crizotinib PF # 51 refractory colorectal cancer 51 placebo controlled Phase 51 hormone refractory 51 transplantation HSCT 51 Alzhemed TM 51 carfilzomib 51 nephrotic syndrome 51 Merck KGaA Erbitux 51 sorafenib tablets 51 Vectibix 51 demethylating agent 51 dacarbazine 51 pazopanib 51 frontotemporal dementia FTD 51 recurrent malignant glioma 51 recurrent wheezing 51 NXL# 51 histiocytosis 51 dyslipidemia 51 fibrotic disease 51 imatinib therapy 51 metastatic gastric 51 advanced metastatic prostate 51 HGPIN 51 hemodialysis patients 51 gliomas 51 Phenoptin 51 chronic HCV 51 nucleotide analog 51 heavily pretreated patients 51 severe aortic stenosis 51 Kaposi sarcoma 51 squamous 51 fatal neurodegenerative disorder 51 polyneuropathy CIDP 51 immunosuppressed 51 ductal adenocarcinoma 51 ELOXATIN 51 neuropsychiatric disorder 51 melphalan prednisone 51 sickle cell disease 51 medulloblastoma tumors 51 myelodysplasia 51 retinal disorders 51 advanced hepatocellular carcinoma 51 gemcitabine 51 registrational trial 51 sorafenib Nexavar 51 metastatic CRPC 51 taxane therapy 51 Severe Sepsis 51 spinal muscular atrophy SMA 51 entinostat 51 Friedreich Ataxia FRDA 51 adenocarcinomas 51 protease inhibitor PI 51 Bevacizumab 51 efalizumab 51 hypertriglyceridemia 51 Sezary syndrome 51 acetonide FA 51 Omnitarg 51 Dacogen 51 KRAS mutant tumors 51 cell lymphoma 51 refractory ovarian cancer 51 androgen independent 51 CDH1 51 HCV genotypes 51 frontotemporal dementia 51 Gaucher disease 51 FOLOTYN 51 Neuroblastoma 51 irinotecan chemotherapy 51 investigational compounds 51 neurodegenerative disease 51 relapsed SCLC 51 GH deficiency 51 Hedgehog Pathway Inhibitor 51 anti TNF 51 Metastatic Colorectal Cancer 51 anti angiogenic agents 51 COU AA 51 MabThera Rituxan 51 Metastatic melanoma 51 Perifosine 51 superficial bladder cancer 51 trastuzumab DM1 T DM1 51 lung metastases 51 childhood leukemias 51 Irinotecan 51 AAT deficiency 51 ofatumumab 51 VZV 51 tumor lysis syndrome 51 progressive multifocal leukoencephalopathy PML 51 primary biliary cirrhosis 51 Exelixis XL# 51 MEK inhibitor 51 Staphylococcus aureus infections 51 degenerative retinal diseases 51 SUTENT 51 SHPT 51 SOD1 gene 51 Acute Leukemia 51 Mantle Cell Lymphoma 51 L Annamycin 51 cell chronic lymphocytic 51 post herpetic neuralgia 51 oral ridaforolimus 51 Duchenne muscular dystrophy 51 LRAT 51 prognostic variables 51 ABSSSI 51 lobular carcinoma 51 predominantly classic subfoveal 50 immune idiopathic thrombocytopenic 50 vascular disrupting agent 50 oritavancin 50 oral JAK1 50 predictive biomarker 50 ccRCC 50 plasma uric acid 50 p# biomarker 50 BCR ABL mutation 50 nonsense mutation 50 chronic HBV infection 50 TEMODAL 50 partial remissions 50 nonalcoholic steatohepatitis 50 leukemias lymphomas 50 dermatofibrosarcoma protuberans 50 Acute Myeloid Leukaemia 50 immunosuppressed patients 50 PRTX 50 lymphocytosis 50 immunodeficiency 50 NAFLD 50 Curaxin CBLC# 50 lysosomal storage diseases 50 osteosarcoma rare 50 invasive breast cancer 50 Systemic lupus erythematosus SLE